Molekulare Pathogenese maligner Lymphome

Leitung

Prof. Dr. M. Dreyling

 

Forschungsprojekte / Forschungsschwerpunkte

  • Molekulare Pathogenese maligner Lymphome

 

Publikationen

Fichtner M, Dreyling M, Binder M, Trepbel M.

The role of B cell antigen receptors in mantle cell lymphoma.

J Hematol Oncol. 2017 Oct 17;10(1):164

 

Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A.

Mutational frequencies of CD79B and MYB88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.

Leuk. Lymphoma. 2017 Sep 3:1-4

 

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukerna SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE,Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Sibert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thomw M, Lenz G.

B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Blood. 2017 Jan 19; 129 (3):333-346

 

Seiler T, Hutter G, Dreyling M.

The Emerging Role of PI3K Inhibitors in the Tretment of Hematological Malignangices: Preclinical Datan and Clinical Progress to Date.

Drugs. 2016 Apr; 76(6):639-46

 

Zoellner AK, Bayerl S, Hutter G, Zimmermann Y, Hiddemann W, Dreyling M.

Temsirolimus inhibis cell growth in combination with inhibitors of the B-cell receptor pathway

Leuk Lymphoma. 2015; 56(12):3393-400

 

Heinrich DA, Weinkauf M, Hutter G, Zimmermann Y, Jurinovic V, Hiddemann W, Dreyling M.

Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.

Br J Haematol. 2015 Feb; 168(4):606-10

 

Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F.

Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.

Nat Med. 2014 Dec; 20(12):1401-9

 

 

Mitarbeiter

  • J. Deuss (cand. Dr. med.)

  • V. Hoffmann (cand. Dr. med.)

  • D. Huber (cand. Dr. vet.)

  • N. Mack (cand. Dr. med.)

  • Dr. A. Mayer

  • A. Schanda (cand. Dr. med.)

  • C. Schwandner (cand. Dr. med.)

  • Dr. E. Silkenstedt

  • Y. Zimmermann (MTA)

  • Dr. A. Zöllner

 

Kontakt

Prof. Dr. M. Dreyling

Klinikum der Universität München - Campus Großhadern

Marchioninistraße 15

D-81377 München

Telefon (089) 4400 - 72202
Fax (089) 4400 - 72201
E-Mail martin.dreyling@med.uni-muenchen.de

 

  Verantwortlich für den Inhalt: Prof. Dr. M. Dreyling; Stand: 15.04.2018